Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.

doi:10.1038/s41591-022-01886-0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.

Nature medicine - 1 Aug 2022

Sartore-Bianchi Andrea, Pietrantonio Filippo, Lonardi Sara, Mussolin Benedetta, Rua Francesco, Crisafulli Giovanni, Bartolini Alice, Fenocchio Elisabetta, Amatu Alessio, Manca Paolo, Bergamo Francesca, Tosi Federica, Mauri Gianluca, Ambrosini Margherita, Daniel Francesca, Torri Valter, Vanzulli Angelo, Regge Daniele, Cappello Giovanni, Marchiò Caterina, Berrino Enrico, Sapino Anna, Marsoni Silvia, Siena Salvatore, Bardelli Alberto

Abstract excerpt

Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of resistance mutations restricts their efficacy. We previously showed that RAS, BRAF and EGFR mutant alleles, which appear in circulating tumor DNA (ctDNA) during EGFR blockade, decline upon therapy withdrawal. We hypothesized that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Circulating Tumor DNA

Share to Colonic Neoplasms

Share to Panitumumab

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to Rectal Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 35915157
DOI: 10.1038/s41591-022-01886-0
PMCID: PMC9386661

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.PMID 35915157Read ↗

Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study.Semantic proximity Read ↗

CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice.Semantic proximity Read ↗

Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancerSemantic proximity Read ↗

Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach.Semantic proximity Read ↗

Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO.Semantic proximity Read ↗

Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA.Semantic proximity Read ↗

Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study.Semantic proximity Read ↗

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Circulating tumour DNA-guided second-line targeted therapy for patients with metastatic colorectal cancer after failure of first-line cetuximab-based treatment: A prospective, phase II trialSemantic proximity Read ↗

The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study.Semantic proximity Read ↗

Loss of RAS Mutations in Liquid Biopsies of Patients With Multi-Treated Metastatic Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.